Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 4

1(20.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

5Total

N/A(2)

Phase 4(1)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07192588Phase 2Active Not Recruiting

A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer

Role: collaborator

NCT04720326Phase 4Active Not Recruiting

Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients

Role: collaborator

NCT04622735Phase 3Completed

Nefopam/Paracetamol Fixed Dose Combination in Acute Pain After Impacted Third Molar Extraction

Role: collaborator

NCT05469503Not ApplicableActive Not Recruiting

Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure

Role: collaborator

NCT04727385Not ApplicableUnknown

Intervertebral DXM Gel Injection in Adults With Painful Lumbar Degenerative Disc Disease

Role: collaborator

All 5 trials loaded